Company profile
Barinthus Biotherapeutics plc. CIK 1828185
Ticker
BRNS (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Germantown, MD 20874
Fiscal year end
2025 (FY)
Key Financials
Revenue
$0
Net income
-$66.43M
Total assets
$98.17M
Total liabilities
$23.88M
Stockholders' equity
$74.21M
Cash & equivalents
$70.46M
Operating income
-$70.56M
Operating cash flow
-$47.98M
Capital expenditures
$37.0K
Fiscal year 2025, via 10-K filed 2026-03-13. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$48.02M
Free cash flow margin
—
Liabilities / assets
24.3%
Equity / assets
75.6%
CapEx / revenue
—
Operating cash flow / net income
0.72×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
$0
-$66.43M
$98.17M
$23.88M
$74.21M
2024
$14.97M
-$61.07M
$160.33M
$30.19M
$130.03M
2023
$802.0K
-$73.35M
$214.51M
$27.51M
$186.78M
2022
$44.70M
$5.34M
$270.21M
$27.00M
$242.90M
2021
$268.0K
-$50.87M
$280.72M
$28.15M
$252.13M
Company Details
SIC code
2834
State of incorporation
X0
Active filer
Yes
Most recent SEC filing
Form EFFECT
2026-09-14
Financials filed via
Form 10-K
filed 2026-03-13
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Germantown, MD 20874
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:33 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.